Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Top 15 Pharmaceuticals Companies in India

In this article, we will take a look at the top 15 pharmaceutical companies in India. For more companies, click Top 5 Pharmaceutical Companies in India.

India is the largest producer of generic medications and vaccines worldwide. It makes up about 20% of the entire amount of generic drug supply in the world. With almost 200 nations receiving Indian pharmaceutical exports, India is a significant pharmaceutical exporter.

In addition, India has a strong network of over 10,500 production facilities, over 3,000 pharmaceutical enterprises, and a manpower pool that is highly skilled. Outside of the US, India has the most pharmaceutical manufacturing facilities that adhere to FDA rules.

More than 500 active pharmaceutical ingredients (APIs) are produced in India, supplying 60,000 generic brands. India now has the third-largest API market in the world as a result. Most supplies are made up of over-the-counter medications used to treat common ailments without endangering life. The pharmaceutical industry’s most important cities are Mumbai, Bangalore, Hyderabad, Pune, Visakhapatnam, and Ahmedabad.

One of the top-performing sectors that provide lucrative business prospects is the Indian pharmaceutical market. In recent years, it has experienced enormous expansion. As the Indian pharmaceutical business transitions from a volume maker to a valued supplier in 2022, investors are turning to this sector for safe haven investments. 

In 2020, the pharmaceutical industry’s main focus was on covid medicines, but by 2022, it had turned to other serious ailments, including cancer and anaemia. In addition, research and development were highly valued in the Indian pharmaceutical business. As a result, India emerged as a global medical behemoth’ in 2022 by growing its R&D ecosystem and increasing pharmaceutical exports. 

India’s pharmaceutical sector is presently worth $50 billion. A recent EY FICCI analysis projects that the Indian pharmaceutical industry will expand to $65 billion by 2024 and to $130 billion by 2030 due to a growing consensus over the need to provide patients with novel, innovative remedies. By 2023, it is anticipated that the worldwide market for pharmaceutical products will reach $1 trillion. With this outlook in mind, let’s start our list of top pharmaceuticals company in India.

Our Methodology

This article will examine the biggest pharma companies in India. The companies are listed in ascending order of total employee count because larger enterprises often have a far higher staff count than smaller ones in the same industry.

Top Pharmaceuticals Companies in India

15. Intas Pharmaceuticals Limited

Number of Employees: 8,000 

Intas Pharmaceuticals Limited is an Indian pharmaceutical company headquartered in Ahmedabad. It produces generic medications as well as contracts clinical research and production. It operates 18 production sites, 15 of which are in India and the remainder in the United Kingdom and Mexico. Intas has a presence in more than 85 countries and is expanding at a CAGR of over 22%.

14. Emcure Pharmaceuticals

Number of Employees: 9,000

Emcure Pharmaceuticals Limited is a multinational pharmaceutical firm based in Pune, India. Emcure’s product line includes tablets, capsules, and injectables. Emcure Pharmaceuticals’ product portfolio, which has a strong chronic and sub-chronic emphasis, includes all the key medicines and is the industry leader in fields including women’s health, blood-related illnesses, HIV, anti-infectives, cardiac care, and vitamins. Emcure Pharmaceuticals has distribution channels and a network that reaches over 70 countries. In addition, the company has 14 production plants and 5 R&D centers. Emcure Pharmaceuticals Limited generated revenue of $730 million in FY 2022. 

13. Piramal Enterprises Limited (NSE:PEL.NS)

Number of Employees: 13,561

Piramal Enterprises Limited conducts operations in the financial services and pharmaceutical industries in India, North America, Europe, Japan, and other countries. Financial Services and Pharmaceuticals Manufacturing and Services are two of its operating segments. The business provides contract development and manufacturing services, such as drug discovery, production, and manufacturing of active pharmaceutical ingredients and formulations, as well as drugs for intrathecal spasticity management, inhalation and injectable anesthesia, injectable pain, antibiotics, and other medications. 

12. Torrent Pharmaceuticals Limited (NSE:TORNTPHARM.NS)

Number of Employees: 13,900

Torrent Pharmaceuticals Limited is the main company of the Torrent Group and is one of the leading Pharma companies in India. The firm is among the leaders in the therapeutic area of cardiovascular, central nervous system, gastrointestinal, and women’s healthcare. Torrent Pharmaceuticals Limited in India originally introduced the idea of specialty marketing. The company is also well-represented in cancer, anti-infectives, diabetology, and pain treatment categories. Additionally, Torrent Pharma has a significant global footprint that spans 40 nations, with activities in developed and rising areas such as the US, Europe, Brazil, and the rest of the globe. The company operates through its 12 fully-owned subsidiaries, having a presence in 40 countries. In 2022, the company’s revenue was $1.1 billion.

11. Abbott India Limited (NSE:ABBOTINDIA.NS)

Number of Employees: 14,000

Abbott India Limited, located in Mumbai, is a publicly traded corporation and a subsidiary of Abbott Capital India Limited. It has one of the quickest rates of growth among Indian pharmaceutical businesses. The business offers trustworthy, high-quality drugs in various therapeutic areas, such as women’s health, gastroenterology, cardiology, metabolic disorders, central nervous system, pain management, pre-term labor, vitamins, sleeplessness, vaccinations, consumer health, etc. Thyronorm, Eptoin, Duphaston, Duphalac, Vertin, Udiliv, Heptral, Digene, Cremaffin, and Prothiaden are some of its well-known trademarks.

10. Biocon Limited (NSE:BIOCON.NS)

Number of Employees: 14,750

Biocon Limited (NSE:BIOCON.NS) makes drugs, therapeutic compounds, and herbal items. Generics, Novel Biologics, Biosimilars, and Research Services are among the company’s segments. Its primary focus areas include diabetes, cancer, immunology, ophthalmology, and bone health issues. It also offers comprehensive services for the research, development, and manufacture of both small and large molecules. The company provides customer assistance in around 120 countries, including Europe and the US. INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor (Everolimus), TACROGRAF (Tacrolimus), ALZUMAb (Itolizumab), and KRABEVA (Bevacizumab) are some of Biocon’s most important brands in India. The company’s consolidated revenue grew 14% to $1.1 billion in FY22.

9. Glenmark Pharmaceuticals Limited (NSE:GLENMARK.NS)

Number of Employees: 15,415

Glenmark Pharmaceuticals Limited develops, produces, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and globally through its subsidiaries. In the therapeutic fields of dermatology, respiratory, and cancer, the firm offers both branded and generic formulations and different active pharmaceutical components. The company operates 14 production plants in Argentina, the Czech Republic, India, and the US. Numerous regulatory agencies inspect these facilities, such as the US-FDA, MHRA UK, and ANVISA Brazil. In addition, being a research-driven company, Glenmark Pharmaceuticals Limited has also made investments in special R&D facilities for international markets. Glenmark Pharmaceuticals Limited brought in $1.48 billion in sales in FY 2022.

8. Alkem Laboratories Ltd. (NSE:ALKEM.NS)

Number of Employees: 17,000

Alkem Laboratories is a pharmaceutical company with international operations. The business creates, produces, and markets pharmaceutical and nutraceutical goods. It has built a strong market position in anti-infective, gastrointestinal, pain management, vitamins, minerals, and nutritional areas, as well as acute treatment. Branded Generics, Generic Drugs, API Nutraceuticals, and Biosimilars are among the company’s product offerings. As of March 31, 2022, Alkem had 21 production facilities—19 in India and 2 in the US. Clavam, Pan 40, Taxim-O, Taxim-D, Taxim Injection, Gemcal, A to Z Tabs, Ondem, Xone, Sumo, Zocef, Pipzo, Swich, Xone XP, and Uprise D3 are some of its top brands.

7. Divi’s Laboratories (NSE:DIVISLAB:NS)

Number of Employees: 17000

Established in 1990, Divi’s Laboratories is a top producer of active pharmaceutical ingredients, exporting top-notch goods to over 95 nations. Europe accounts for most of the company’s sales, followed by North America, India, and Asia. The business views investing in mergers and acquisitions as a possible part of its operational growth plan to boost its R&D, production, and marketing capabilities. In FY22, Divi’s Laboratories generated $1.1 billion in revenue.

6. Lupin Limited (NSE:LUPIN.NS)

Number of Employees: 20,000

Lupin Limited develops, produces, distributes, and markets a wide range of biotechnology products, branded and generic formulations, and active pharmaceutical ingredients (APIs). Cardiovascular, asthma, diabetes management, pediatrics, central nervous system, gastroenterology, anti-infectives, nonsteroidal anti-inflammatory medications (NSAIDs), anti-TB, and cephalosporins are among its areas of specialization. With 18 production facilities, Lupin sells its goods in more than 100 nations. India, the US, Japan, Europe, South Africa, the Philippines, and Australia are key markets for the company. The Indian pharmaceutical firm Lupin Limited announced net revenues of $1.96 billion for the fiscal year 2022.

Click to continue reading and see Top 5 Pharmaceuticals Company in India.

Suggested articles:

Disclosure: None. Top 15 Pharmaceuticals Company in India is originally published on Insider Monkey.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

  • It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
  • It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
  • It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

  • The AI infrastructure supercycle
  • The onshoring boom driven by Trump-era tariffs
  • A surge in U.S. LNG exports
  • And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…